Browse the evidence

Orforglipron treatment resulted in significant improvements in waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels compared to placebo.

Orforglipron may improve several cardiovascular and metabolic risk factors in obese adults.

All intermittent fasting and continuous energy restriction diet strategies reduced body weight when compared with ad-libitum diet.

Intermittent fasting and continuous energy restriction can be effective strategies for weight loss in diverse populations.

Alternate day fasting was the only form of intermittent fasting diet strategy to show benefit in body weight reduction compared with continuous energy restriction.

Alternate day fasting may be a more effective intermittent fasting strategy for weight loss compared to continuous energy restriction.

In comparisons between intermittent fasting strategies, alternate day fasting lowered total cholesterol, triglycerides, and non-high density lipoprotein compared with time restricted eating.

Alternate day fasting may improve lipid profiles more effectively than time restricted eating.

Oral semaglutide at a dose of 25 mg once daily resulted in a mean reduction in body weight of -13.6% from baseline to week 64.

Oral semaglutide may be an effective treatment option for weight loss in adults with obesity.

Participants in the oral semaglutide group were significantly more likely to achieve body-weight reductions of 5% or more, 10% or more, 15% or more, and 20% or more compared to the placebo group.

Oral semaglutide may help patients achieve significant weight loss milestones.

Limiting consumption of ultra-processed foods may be an effective strategy for obesity prevention and treatment.

Encouraging clients to limit ultra-processed food intake may support weight management efforts.

VLCD and COMB resulted in a 5.4 and 7 percentage-point greater weight loss than SEM, respectively.

Practitioners should consider VLCD or its combination with Semaglutide for greater weight loss in patients with T2D.

HbA1c and fasting glucose reduced significantly in all groups.

All interventions can be effective in improving glycaemic control in T2D patients.

Semaglutide use is associated with a substantial decrease in long-term relative body weight of -12.1% compared to placebo.

Semaglutide can be considered an effective treatment option for weight loss in patients with obesity who do not have diabetes.

33.4% of participants randomized to semaglutide achieved ≥20% weight loss compared to 2.2% with placebo.

A significant proportion of patients may achieve substantial weight loss with semaglutide, making it a viable option for obesity management.

In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg for 32 weeks led to a mean percentage change in body weight from baseline of -10.09%.

Mazdutide may be an effective treatment option for weight loss in adults with obesity or overweight.

In the 6-mg mazdutide group, the mean percentage change in body weight from baseline at week 32 was -12.55%.

Higher doses of mazdutide may lead to greater weight loss in adults with obesity or overweight.

73.9% of participants in the 4-mg mazdutide group achieved a weight reduction of at least 5% at week 32.

A significant proportion of adults with obesity or overweight may benefit from mazdutide treatment.

Tirzepatide 15 mg had the highest efficacy compared with placebo for achieving ≥15% weight loss (risk ratio 10.24, 95% CI: 6.42-16.34).

Tirzepatide 15 mg is highly effective for significant weight loss in overweight and obese patients.

Tirzepatide ranked in the top three across weight-related parameters, glycemic profile, lipid parameters, and blood pressure.

Tirzepatide may provide comprehensive metabolic benefits beyond weight loss.

Tirzepatide (TZP) resulted in a mean body weight loss of 16.7 kg compared to 8.3 kg with placebo (PBO) after 18 weeks (p<0.001).

Tirzepatide may be an effective treatment for weight loss in individuals with obesity.

TZP significantly decreased food intake during lunch and dinner compared to PBO.

TZP may help reduce overall food consumption in individuals with obesity.

TZP significantly lowered appetite and food cravings compared to PBO.

TZP may be beneficial in managing appetite and cravings in individuals with obesity.

Weight management treatments (WMT) increased the probability of achieving 5% or greater weight loss.

Implementing WMT can significantly enhance weight loss outcomes for patients.

Structured aerobic exercise at a dose of 20 KKW produced significant weight loss of -2.1 ± 0.7 kg.

Aerobic exercise at a higher intensity may lead to weight loss, but results may be less than anticipated.

QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.

Weight loss can significantly reduce cardiovascular risk in individuals with T2DM.

Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.

Achieving weight loss and diabetes remission can significantly improve long-term cardiovascular health outcomes.

The combination of cagrilintide and semaglutide (cagrANDsema) reduced weight by -14.13 kg compared to placebo.

CagrANDsema is an effective treatment option for weight loss in individuals with obesity.